Both liraglutide and tetrahydrocurcumin ameliorated NAFLD by increasing the mRNA levels of Nrf2, HO-1, GCLM, and NQO1 [9,10]. Here, NFE2L2 is linked to metabolic dysfunction-associated steatotic liver disease.